secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001104659-23-085347
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode receives Nasdaq delisting notice; equity below $2.5M requirement
--------------------------------------------------------------------------

- Nasdaq rejected TransCode's compliance plan to regain stockholders' equity of at least $2.5M.
- Company intends to appeal to Nasdaq Hearings Panel by August 2, 2023; appeal stays delisting pending hearing.
- If no appeal, common stock (RNAZ) will be suspended from trading on Nasdaq at open on August 4, 2023.
- Non-compliance initially disclosed on May 16, 2023; compliance plan submitted June 30 and supplemented July 24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923085347/0001104659-23-085347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923085347/tm2322311d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-085347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer